Home stock market IPO's Gland pharma IPO Review|Gmp|Grey Market|Details

Gland pharma IPO Review|Gmp|Grey Market|Details

gland pharma grey market premium, gland pharma ipo 2020 grey market, gland pharma ipo details,

Gland Pharma IPO Grey Market Premium is trading at Rs. 150 Before its open for subscribtion. Hence, The Company has decided to alot 35% of its IPO to retails Investors which is huge. The comPany is able to deliver good results in the past,

Gland Pharma IPO Subscribtion Will be open on november 9th-11th 2020. The investors are looking forward to subscribe this Ipo as the grey market premium for this ipo is trading around 20%. You can see huge subscribtion for thia ipo.

Gland Pharma Ipo 2020 Complete Details :

IPO DateNov 9, 2020 – Nov 11, 2020
Issue TypeBook Built Issue IPO
Issue Size43,196,968 Eq Shares of ₹1
(aggregating up to ₹6,479.55 Cr)
Fresh Issue8,333,333 Eq Shares of ₹1
(aggregating up to ₹1,250.00 Cr)
Offer for Sale34,863,635 Eq Shares of ₹1
(aggregating up to ₹5,229.55 Cr)
Face ValueRs.1 per equity share
IPO PriceRs.1490 to Rs.1500 per equity share
Market Lot10 Shares
Min Order Quantity10 Shares
Listing AtBSE, NSE

Gland Pharma IPO Tentative Date :

Offer Opens OnNov 9, 2020
Offer Closes OnNov 11, 2020
Finalisation of Basis of AllotmentNov 17, 2020
Initiation of RefundsNov 18, 2020
Credit of Shares to Demat AccountNov 19, 2020
IPO Shares Listing DateNov 20, 2020

Gland Pharma Lot Size and Price :

ApplicationLotsSharesAmount
Minimum110Rs.15,000
Maximum13130Rs.195,000

Gland Pharma IPO 2020 Promoters Holding :

Pre Issue Share Holding74%
Post Issue Share Holding

Gland Pharma promoters are: 1) Fosun singapore 2) Shanghai fosun Pharma.

Gland Pharma Company’s Financials:

ParticularsFor the year ended (Rs in million)
30-June-2031-Mar-2031-Mar-1931-Mar-18
Total AssetRs.46,912.65Rs.40,860.39Rs.35,235.49Rs.29,294.68
Total Revenue YOYRs.9,162.89Rs.27,724.08Rs.21,297.67Rs.16,716.82
Profits Earned After TaxRs.3,135.90Rs.7,728.58Rs.4,518.56Rs.3,210.51

Gland Pharma company financial analysis for this ipo. The company balance sheet looks very stable and hence they are able to deliver good results for every year. The assests is signicantly increasing every year and profits after tax is growing at 20% every year. The return on equity is at 15%.

About Gland Pharma Company Information:

Incorporated in 1978, Gland Pharma is one among the most important and fastest-growing injectable-focused companies within the us of America from 2014-2019. the corporate features a portfolio of injectable products across various therapeutic areas and delivery systems.

It has a presence in sterile injectables, oncology and ophthalmics, and focuses on complex injectables, NCE-1s, First-to-File products and 505(b) (2) filings. It sells its products through a business-to-business (B2B) model in additional than 60 countries across the world (as of June 30, 2020). The list of nations includes the us, Europe, Canada, Australia, India, etc.

Gland Pharma has seven manufacturing facilities in India, comprising four finished formulations facilities with a complete of twenty-two production lines and three API facilities. it’s a diary of operating a B2B model with some leading pharmaceutical companies like Sagent Pharmaceuticals Inc., Apotex Inc., Fresenius Kabi USA LLC, Athenex Pharmaceutical Division LLC (US), etc.

This B2B model is complemented by a business-to-customer (B2C) model in India – the house market of Gland Pharma, leveraging its brand strength and sales network.

Also Read : lic IPo 2020

1. Strengths Of Gland Pharma IPO :

  • Gland Pharma Ipo has extensive useand vertically integrated injectables manufacturing capabilities with a uniform regulatory compliance track record in this pharma sector.
  • It features a diversified B2B-led model across markets, complemented by a targeted B2C model in India.
  • Gland Pharma has developed an in depth portfolio of complex products supported by internal R&D and regulatory capabilities.
  • The company features a diary of growth and profitability from a diversified revenue base with healthy cash flowsIt has an experienced management and qualified team.

2. Objects of the Offer – Gland Pharma IPO

Gland Pharma Limited proposes to utilize internet proceeds from this issue towards the subsequent objects:Funding incremental capital requirements of our Company;Funding cost requirements of our Company; andGeneral corporate purposes.

3. Risk Factors for this IPO

The injectable pharma manufacturing industry is heavily regulated and Gland Pharma’s business activities require various approvals, licenses, registrations and permissions. If there’s any change to such regulations or failure or delay in obtaining necessary permits or approvals, or if such permits or approvals are revoked or not renewed for any reason, its business, economic condition, cash flows, and results of operations could also be adversely affected.

The success of Gland Pharma depends on its business arrangements with its marketing partners and customers for the sale of its products. If any of those arrangements is terminated for any reason, or if its marketing partners fail to satisfy their obligations under the relevant agreements or otherwise don’t effectively sell or market our products, or if its relationships with any of its marketing partners and customers are disrupted, its business, economic condition, cash flows, and results of operations could also be adversely affected.
The success of Gland Pharma depends on its business arrangements with its marketing partners and customers for the sale of its products. If any of those arrangements is terminated for any reason, or if its marketing partners fail to satisfy their obligations under the relevant agreements or otherwise don’t effectively sell or market our products, or if its relationships with any of its marketing partners and customers are disrupted, its business, economic condition, cash flows, and results of operations could also be adversely affected.

Know More: Mutual funds Begineers

If its API production is interrupted or it fails to supply or procure high-quality APIs within the quantities it requires during a cost-effective manner, sales of its products might be delayed or interrupted.Any manufacturing or internal control problems may disrupt Gland Pharma’s business operations, damage its reputation for high-quality production and expose it to potential litigation or other liabilities, which might negatively impact its business prospects, cash flows, results of operations, and economic condition.

Gland Pharma’s business depends on the sale of its products to key customers and in key markets, particularly the us, Europe, Canada, and Australia. The loss of such customers or a big reduction in purchases by such customers in these markets could materially adversely affect its business, cash flows, results of operations, and economic condition.A significant portion of the company’s income depends on sales of its key injectable formulations. If the sales volume or pricing of such products declines within the future, or if it can not sell any of the key compounds for any reason, its business, economic condition, cash flows, and results of operations might be materially adversely affected.

Gland Pharma is vulnerable to product liability claims and associated risks of litigation that would expose it to material liabilities, loss in revenues, and increased expenses and thus may have a cloth adverse effect on its business.The company’s profitability, cash flows, and results of operations could also be adversely affected within the event of increases within the price of raw materials, fuel costs, labor, or other inputs, a shortfall within the supply of raw materials also as a disruption within the supply of machinery and equipment required for its manufacturing facilities.

Gland Pharma has a decent requirements of capital. If it experiences insufficient cash flows to fund its capital requirements or if it’s unable to supply collateral to get letters of credit, bank guarantees, and performance bonds in sufficient quantities, there could also be an adverse effect on its business, cash flows, and results of operations.

Gland Pharma Ipo Grey Market Premium:

Gland Pharma IPO grey market is trading quiet well in the grey market. The demand for ipo this quarter is been significant. Hence The pharma IPO is seen alot of interest from the investors. Grey market for this ipo is at around Rs. 200.

Gland Pharma IPO GMP And Review :

Gland pharma IPO GMP 1500-1700 now and the price for this ipo in increasing in the grey market. the surge in price in the grey market shows interest in the retail investors as well.

Gland pharma IPo review, If you are looking for a decent pharma company with good returns and stable growth this is the company you should invest.

Disclaimer: All this information is for study purpose. If you are looking to invest its your personal decision. Just helping you to decide the best one.

LEAVE A REPLY

Please enter your comment!
Please enter your name here